News

Parabilis Medicines to Present Overview of Ongoing Phase 1/2 Study of FOG-001, a β-cateninTCF4 Inhibitor, at Upcoming Medical Meetings
Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people ...